Delphi Genetics and EUROGENTEC s.a. Collaborate for Antibiotic Resistance-Gene Free GMP Manufacturing
Published: Nov 13, 2008
LIEGE, Belgium--(BUSINESS WIRE)--Eurogentec SA and Delphi Genetics SA have signed an agreement to co-market the use of StabyDNA technology for GMP manufacturing purposes. The antibiotic resistance-gene free technology, developed and owned by Delphi Genetics allows for clone selection, plasmid stability and manufacturing of plasmids and proteins without the use of antibiotics. Under the agreement Eurogentec will promote Delphi Genetics’ StabyDNA technology for use in GMP manufacturing on an exclusive basis. The financial terms of the agreement were not disclosed.